Navigating OBBBA Compliance: Managing New R&D and Business Interest Deduction Rules

Introduction: A New Compliance Horizon for 2026

The One Big Beautiful Bill Act (OBBBA) has fundamentally reshaped two of the most consequential provisions in the corporate tax code: the treatment of research and experimentation expenditures under Section 174 and the business interest deduction limitation under Section 163(j). For businesses that spent the past several years absorbing the compliance burden and cash-flow strain imposed by the Tax Cuts and Jobs Act's amortization requirements and tightened interest limitations, OBBBA offers meaningful relief. But relief is not the same as simplicity. As 2026 approaches, companies must recalibrate their tax planning, revisit prior elections, and prepare for a wave of implementing guidance from Treasury and the IRS.

This article examines the practical compliance implications of OBBBA's R&D and business interest provisions and outlines the strategic steps sophisticated taxpayers should be taking now.

The Return to Immediate R&D Expensing

Since 2022, taxpayers have been required to capitalize domestic research and experimental expenditures under Section 174 and amortize them over five years (fifteen years for foreign research), a departure from the historical practice of immediate deduction. This shift created significant cash-tax burdens for R&D-intensive businesses, particularly technology, life sciences, and manufacturing firms that had structured their financial planning around full current-year deductibility.

OBBBA restores immediate expensing for domestic research and experimental expenditures, reversing the amortization mandate that many practitioners viewed as an unintended consequence of prior tax legislation's revenue-offset mechanics. For businesses, this restoration carries several practical implications:

• Transition elections matter. Taxpayers with unamortized R&D costs on their books from the 2022–2025 period will need to evaluate available transition rules, including whether and how to accelerate remaining deductions.
• Method changes require careful documentation. Reverting to expensing will likely require accounting method change filings, and businesses should not assume automatic consent procedures will apply uniformly across all fact patterns.
• State conformity is not guaranteed. Many states decouple from federal R&D treatment, and businesses operating in multiple jurisdictions must separately track state-level treatment to avoid mismatches between federal and state taxable income.
• Foreign research treatment remains distinct. Businesses with cross-border research operations should confirm whether foreign R&D costs continue to be subject to longer amortization periods, as OBBBA's relief is targeted primarily at domestic research activity.

Companies should not wait for finalized IRS guidance to begin this analysis. Given the magnitude of deferred tax assets and liabilities tied to R&D capitalization, finance and tax teams should be modeling the earnings and cash-tax impact of reversion now, particularly for purposes of financial statement disclosures and estimated tax payments.

Business Interest Deduction: A More Favorable ATI Calculation

The second major area of change involves Section 163(j), which limits the deductibility of business interest expense to a percentage of adjusted taxable income (ATI). Since 2022, the calculation of ATI excluded add-backs for depreciation, amortization, and depletion, effectively shifting the limitation from an EBITDA-based standard to a more restrictive EBIT-based standard. For capital-intensive businesses carrying significant debt, this change materially reduced the amount of deductible interest expense, even where overall leverage remained unchanged.

OBBBA restores the more favorable EBITDA-based approach to calculating ATI, allowing businesses to add back depreciation, amortization, and depletion when determining the interest deduction limitation. This is a significant and welcome development for leveraged businesses, private equity portfolio companies, and capital-intensive industries such as real estate, energy, and manufacturing.

Key compliance considerations include:

• Recomputing carryforwards. Businesses with disallowed business interest expense carryforwards from prior years should reassess how those amounts interact with the newly expanded ATI calculation going forward.
• Entity structure implications. Partnerships and S corporations should revisit how Section 163(j) limitations are allocated among partners and shareholders, as the increased ATI capacity may free up previously suspended interest deductions at the entity or owner level.
• Debt capacity modeling. Treasury and finance teams should revisit debt capacity models and covenant compliance analyses that were built around the more restrictive EBIT-based limitation, as the shift may materially change effective borrowing capacity.
• Interaction with R&D expensing. Because the reversion to immediate R&D expensing may reduce reported taxable income in the near term (relative to amortized treatment), businesses should model the combined effect of both provisions on ATI and overall tax liability, since the two changes interact directly through the taxable income base.

Strategic and Compliance Priorities for 2026

Given the scope of these changes, businesses should treat 2026 as a transition year requiring proactive governance rather than passive compliance. Recommended priorities include:

• Conduct a comprehensive impact assessment across R&D capitalization, interest expense limitations, and their combined effect on effective tax rate and cash-tax liability.
• Review accounting method change procedures early, particularly for R&D expensing reversion, to avoid delays or disputes over automatic consent eligibility.
• Reassess state tax positions independently, given the likelihood of continued state nonconformity with federal treatment.
• Update financial forecasts and covenant analyses to reflect increased interest deduction capacity and its downstream effects on liquidity planning.
• Monitor forthcoming IRS guidance closely, as implementing regulations, notices, and procedural guidance will shape the mechanics of transition elections and reporting requirements.

Conclusion

OBBBA represents a substantial and largely favorable recalibration of the R&D and business interest deduction rules, but the transition itself introduces meaningful complexity. Businesses that move deliberately—reassessing accounting methods, recalculating carryforwards, and modeling the interplay between these two provisions—will be well positioned to capture the intended benefits while avoiding compliance missteps. Given the technical nuance involved and the pace at which regulatory guidance is expected to develop, businesses should engage experienced tax counsel to guide implementation and ensure their positions withstand scrutiny as the new framework takes hold in 2026 and beyond.